Short interposition with a small-diameter prosthetic graft for flow reduction of a high-flow arteriovenous fistula.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
01 2021
Historique:
received: 08 10 2019
accepted: 03 05 2020
pubmed: 31 5 2020
medline: 4 5 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

The objective of this study was to evaluate the outcome of a short interposition using a small-diameter prosthetic graft as a flow-limiting procedure to manage symptomatic high-flow arteriovenous fistula (AVF). A retrospective review of medical records on a case series was conducted. From June 2004 to April 2017, there were 25 patients with clinical symptoms of high output cardiac failure and progressive dilation of aneurysmal fistula vein due to high-flow AVF (≥1.5 L/min) who underwent short interposition with a 5-mm prosthetic graft at Saitama Medical Center. The primary outcome was the relief of clinical symptoms; other outcome measures included technical success, surgical complications, patency of vascular access, and postoperative changes in local and systemic hemodynamics as assessed by Doppler ultrasound. Twenty-five patients underwent short interposition for cardiac indications (n = 16) and aneurysmal dilation (n = 9). The technical success rate was 100%. The clinical symptoms were relieved in 24 patients (96.0%). Mean reduction in access blood flow was 52.4%. Cumulative primary unassisted patency rates (± standard error) at 1 year, 2 years, and 3 years were 76.2% ± 9.3%, 70.4% ± 10.3%, and 58.1% ± 11.6%, respectively. Secondary patency rates (± standard error) at 1 year, 2 years, and 3 years were 81.8% ± 8.2%, 71.5% ± 9.9%, and 71.5% ± 9.9%, respectively. Complications included access occlusion due to late thrombosis (n = 5 [21.7%]) and graft infection (n = 1 [4.3%]) in the median follow-up period of 3.9 years. Short interposition with a prosthetic graft is a simple, effective, and durable treatment option for end-stage renal disease patients with cardiac symptoms and progressive dilation of the fistula vein due to high-flow AVF, offering clinical symptom resolution while preserving the autologous behavior of the initial access.

Identifiants

pubmed: 32473337
pii: S0741-5214(20)31291-X
doi: 10.1016/j.jvs.2020.05.035
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

285-290

Informations de copyright

Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Takuya Hashimoto (T)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Daisuke Akagi (D)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan; Department of Vascular Surgery, Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan.

Satoshi Yamamoto (S)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Masamitsu Suhara (M)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Osamu Sato (O)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Juno Deguchi (J)

Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Electronic address: deguchi@saitama-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH